Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 423 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Botulinum toxin(Botox) Clear all

Conditions: Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions: Botox® injection, Mid-urethral sling; Drug · Device
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more

Conditions: Upper Limb Spasticity
Interventions: ABBV-950, BOTOX, Placebo for ABBV-950; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 9
States / cities: Carlsbad, California • Downey, California • Fresno, California + 6 more

Conditions: Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions: Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24,, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Westminster, California

Conditions: Neuropathic Back Pain, Spinal Cord Injury
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Keloid
Interventions: Botulinum toxin type A, Vehicle; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Secondary Headache Disorder
Interventions: Botulinum Toxin type A; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cerebral Palsy
Interventions: Botulinum Toxin A; Drug
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 4 Years to 12 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Dystonia
Interventions: ABP-450, Placebo; Drug
Lead sponsor: AEON Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 17 more

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxins, Type A, Placebos; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more

Conditions: Upper Facial Lines, Glabellar Lines
Interventions: TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Glendale, Arizona • Newport Beach, California + 17 more

Conditions: Dermatological Non-Disease
Interventions: Botox Cosmetic Injectable Product, Juvéderm Voluma XC, Juvéderm Volbella XC; Drug · Device
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 24 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Migraine Disorders
Interventions: Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more

Conditions: Spasticity
Interventions: Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo; Drug
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more

Conditions: Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions: Intra-detrusor injection of Onabotulinumtoxin-A; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Dystonia, Tardive Dystonia
Interventions: Low Dose - AbobotulinumtoxinA; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Levator Ani Syndrome With Pain and/or Constipation Symptoms.
Interventions: Biofeedback therapy, Botulinum Toxin Type A Injection; Behavioral · Procedure
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Migraine
Interventions: OnabotulinumtoxinA, Normal saline (placebo); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bariatric Surgery, Postoperative Nausea and Vomiting
Interventions: Botulinum toxin pyloroplasty, Normal saline pyloric injection; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years to 90 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Lateral Canthal Lines, LCL, Crow's Feet
Interventions: botulinum toxin, Type A, Vehicle; Biological
Lead sponsor: Eirion Therapeutics Inc.; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Pinellas Park, Florida • Yardley, Pennsylvania • Norfolk, Virginia

Conditions: Upper Facial Lines
Interventions: BOTOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Vista, California + 4 more

Conditions: Interstitial Cystitis
Interventions: Onabotulinumtoxin A, injections upper aspect of trigone of urinary bladder, injections on posterior bladder wall excluding the trigone; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glabellar Lines
Interventions: AGN-151586, OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 8
States / cities: Scottsdale, Arizona • Newport Beach, California • Redondo Beach, California + 5 more

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Sling vs Botox for Mixed Incontinence

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

ASIS for Botox in Chronic Migraine

Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

The Effect of Botulinum Toxin A on Headache Attributed to TMD

The Effect of Botox on Children With Cerebral Palsy

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines

Combination Facial Aesthetic Treatment in Millennials

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

Dysport for the Treatment of OMD

Comparison of Biofeedback vs. Botox Injection to Treat Levator Ani Syndrome

Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)

Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy

ET-01 in Subjects With Lateral Canthal Lines, LCL-209

A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Intravesicular Onabotulinumtoxin A in Interstitial Cystitis

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Preoperative BOTOX® Injection for Large Ventral Hernia Repair